Mode
Text Size
Log in / Sign up
N/A N=394

Observational Study on 2-chloroprocaine Hydrochloride 1%

Neurological Complication, in Particular TNS or CES

Enrolled (actual)
394
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcome: Primary: Number of Participants With Adverse Events — 9; 5 participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
2-chloroprocaine hydrochloride, 1% (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Sintetica SA
Primary completion
Oct 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Adverse Events
9; 5
PRIMARY
Number of Participants With Symptoms in Follow-Up Questionnaire at 24 Hours
4; 3; 1; 1
PRIMARY
Number of Participants With Symptoms in Follow-Up Questionnaire at 7 Days
3; 1; 1; 2

Summary

The present study aims to evaluate the relationship between spinal block with 1% solution of 2-chloroprocaine hydrochloride and the onset of all possible neurological adverse events, with particular attention to Transient Neurological Symptoms (TNS) and Cauda Equina Syndrome (CES).

Eligibility Criteria

Inclusion Criteria

  • Male/female adult patients
  • Ability to comprehend the full nature and purpose of the study
  • Ability to co-operate with the Investigator and to comply with the requirements of the entire study
  • Signed written informed consent of the patients prior to inclusion in the observational study. The signature has to be done before the elective surgery.
  • Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes.

Exclusion Criteria

  • Hypersensitivity to the active substance, medicinal products of the PABA (para-aminobenzoic acid) ester group, other ester-type local anaesthetics or to any of the excipients (Hydrochloric acid 1N for pH adjustment, Sodium chloride, Water for injection)
  • General and specific contra-indications to spinal anaesthesia regardless of the local anaesthetic used, should be taken into account (e.g. decompensated cardiac insufficiency, hypovolemic shock….)
  • Intravenous regional anaesthesia (the anesthetic agent is introduced into the limb and allowed to set in while tourniquets retain the agent within the desired area)
  • Serious problems with cardiac conduction,
  • Severe anaemia,
  • It is also necessary to take into consideration general and specific contraindications for the technique of spinal anaesthesia = intrathecal anaesthesia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02067806). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search